Sera Level and Polymorphism of Interleukin-33 Gene in Iraqi Females Patients with Breast Cancer

Main Article Content

Asmaa M. Salih Almohaidi
Hazima Mossa Al-Abassi
Zainab Jalil Abdulkareem
Maha Mhammed Al-Sayyid


Interleukin-33 [IL-33] is a specific ligand for the ST2 receptor, and a member of the IL-1 family. It is a dual-function protein that acts both as an extracellular alarmin cytokine, and an as an intracellular nuclear factor participates in maintaining barrier function by regulating gene expression of IL-33 modulating tumor growth and anti-tumor immunity in cancer patients. The present study aimed to investigate the role of IL-33 serum level and gene polymorphism in Iraqi women with breast cancer. Materials and methods: Blood samples were collected from 66 Iraqi patient women diagnosed with breast cancer, which were divided into two groups: pre-treatment [PT] and under treatment with chemotherapy [UTC] patients in addition to 34 apparently healthy women who were matched with patients as a control. ELISA technique was used to determine the IL-33 serum level. The PCR-RFLP technique was performed to determine IL-33 gene polymorphisms at single nucleotide polymorphism SNP [rs1929992]. Results: IL-33 serum level recorded lower significant in PT [182.22 ± 29.86pg/ml] and UTC [129.87 ± 45.11pg/ml] patients compared with control [258.08 ± 39.54 pg/ml] under [p<0.05]. In a polymorphism study on IL-33 SNP [rs1929992] showed AG genotype recorded the high frequency in control than in patients [76.47, 58.46] compared to other genotypes AA, GG with no significant difference according to fisher’s exact probability. In conclusion: IL-33 serum level decreased after performing surgery on breast cancer patients. There was no association between breast cancer development and IL-33 SNP [rs1929992]. The heterozygous genotype AG was a common genotype in the Iraqi population. Allele G had an environmental fraction, while allele A had preventive fraction, which related to increasing the level of IL-33 with both genotypes AA, AG in the healthy control group, in contrast with GG genotype which showed the highest level in the patients’ group.

Article Details

How to Cite
M. Salih Almohaidi, A., Mossa Al-Abassi, H., Jalil Abdulkareem, Z., & Mhammed Al-Sayyid, M. (2020). Sera Level and Polymorphism of Interleukin-33 Gene in Iraqi Females Patients with Breast Cancer. Ibn AL- Haitham Journal For Pure and Applied Sciences, 34(1). Retrieved from